Cannabis Was Ready For Wall St., But Was Wall St. Ready For Cannabis?
Trulieve and Glass House’s NYSE uplistings mark a milestone, but experts warn of investor education gaps, geographic complexity, and a five-year capital drought.
Is Jazz still the best cannabis stock after federal rescheduling?
Jazz Pharmaceuticals JAZZ is best known for its market-leading oxybate franchise, but the company has also carved out a unique position in cannabinoid-based medicine. It markets Epidiolex, the first …
Tilray Brands (NASDAQ:TLRY) Deepens Its Medical Cannabis Reach
Tilray Brands advances international medical cannabis access while regulatory progress, beverages, wellness brands, and operational discipline shape its evolving business outlook.
Should you buy Tilray Brands stock before July 28?
Tilray will release its year-end numbers next week, which could have a significant impact on the stock.
ACB stock down 28% in three months: Time to buy the dip or cash out?
Shares of Aurora Cannabis ACB have lost 27% over the past three months, despite the cannabis operator delivering better-than-expected fourth-quarter 2026 (year ended March 2026) revenues and earnings.
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Is Jazz still the best cannabis stock after federal rescheduling?
Jazz Pharmaceuticals JAZZ is best known for its market-leading oxybate franchise, but the company has also carved out a unique position in cannabinoid-based medicine. It markets Epidiolex, the first …
Tilray Brands (NASDAQ:TLRY) Deepens Its Medical Cannabis Reach
Tilray Brands advances international medical cannabis access while regulatory progress, beverages, wellness brands, and operational discipline shape its evolving business outlook.
Should you buy Tilray Brands stock before July 28?
Tilray will release its year-end numbers next week, which could have a significant impact on the stock.
ACB stock down 28% in three months: Time to buy the dip or cash out?
Shares of Aurora Cannabis ACB have lost 27% over the past three months, despite the cannabis operator delivering better-than-expected fourth-quarter 2026 (year ended March 2026) revenues and earnings.
Tilray’s stock is down over 50% this year. Has it become a bargain buy?
The cannabis stock recently hit a new 52-week low.
Is Green Thumb stock oversold? The case for 100% upside.
It’s a rare gem among marijuana stocks, for several reasons.
The Easiest Way to Bet on US Cannabis Is This One ETF
One ETF promises investors a clean shot at the U.S. cannabis trade, but the inside of this fund is stranger than its simple ticker suggests.
DEA Rescheduling Hearing Puts Cannabis Stocks in Focus Ahead of a July 15 Deadline
The DEA’s cannabis rescheduling hearing runs through a July 15 deadline, putting cannabis stocks and the MSOS ETF in focus.
Innovative Industrial Properties: Cannabis Rescheduling Progress Reinforces The Re-Rating Thesis
Innovative Industrial’s AFFO was stable at $1.88/share, and leverage is still low for a REIT. Click here to read why IIPR stock is a Strong Buy.
Recent Comments